AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33039635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic angioembolization
Number of subjects: 146
Study 35995058 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based aftercare
Number of subjects: 300
Study 35995058 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 300
Study 35995058 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face (F2F) therapy
Number of subjects: 300
Study 32084353 — intervention group
Group type: EXPERIMENTAL
Intervention: BBM combined with simvastatin
Number of subjects: 12
Study 32084353 — intervention group
Group type: COMPARATOR
Intervention: BBM alone
Number of subjects: 12
Study 36138055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 40
Study 36138055 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (placebo needles)
Number of subjects: 40
Study 35435981 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring
Number of subjects: 0
Study 35435981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dozing
Number of subjects: 0
Study 35435981 — intervention group
Group type: EXPERIMENTAL
Intervention: Right arm fat mass
Number of subjects: 0
Study 32896504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone group (3‐day, low‐dose glucocorticoid treatment plus conventional treatment; 63 patients)
Number of subjects: 125
Study 32896504 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment only; 62 patients)
Number of subjects: 125
Study 32705460 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training-Oregon model (PMTO)
Number of subjects: 126
Study 32705460 — intervention group
Group type: COMPARATOR
Intervention: Family-based services as usual (SAU)
Number of subjects: 126
Study 35901309 — intervention group
Group type: EXPERIMENTAL
Intervention: Second glaucoma drainage device (SGDD)
Number of subjects: 42
Study 35901309 — intervention group
Group type: COMPARATOR
Intervention: Transscleral cyclophotocoagulation (CPC)
Number of subjects: 42
Study 35901309 — intervention group
Group type: EXPERIMENTAL
Intervention: SGDD
Number of subjects: 42
Study 33124663 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (4 weeks)
Number of subjects: 55
Study 33124663 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin plus Vildagliptin (4 weeks of rapamycin plus 12 weeks of vildagliptin)
Number of subjects: 55
Study 33124663 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (control group)
Number of subjects: 55
Study 32404518 — intervention group
Group type: EXPERIMENTAL
Intervention: +F+H
Number of subjects: 89
Study 32404518 — intervention group
Group type: COMPARATOR
Intervention: -F-H
Number of subjects: 89
Study 32404518 — intervention group
Group type: COMPARATOR
Intervention: -F+H
Number of subjects: 89
Study 34890936 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model based on pre-NAC MRI features (model 1)
Number of subjects: 147
Study 34890936 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model based on post-NAC MRI features (model 2)
Number of subjects: 147
Study 34890936 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model based on both pre- and post-NAC MRI features (model 3)
Number of subjects: 147
Study 34890936 — intervention group
Group type: COMPARATOR
Intervention: Clinical model for predicting systemic recurrence
Number of subjects: 147
Study 34890936 — intervention group
Group type: COMPARATOR
Intervention: Comparison of model 3 to clinical model
Number of subjects: 147
Study 34301334 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group programme and access to online resources
Number of subjects: 92
Study 34301334 — intervention group
Group type: COMPARATOR
Intervention: Access to online resources only
Number of subjects: 92
Study 34678491 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 6000
Study 34678491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 33769174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA) 100 mg/day
Number of subjects: 277
Study 33769174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 32767679 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06763809 (2.3%, 0.8%, 0.23%)
Number of subjects: 17
Study 32767679 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 17
Study 32767679 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 17
Study 32767679 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 17
Study 35459446 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 169
Study 35459446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study 34959879 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD+
Number of subjects: 27
Study 34959879 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD
Number of subjects: 27
Study 34959879 — intervention group
Group type: COMPARATOR
Intervention: HAD
Number of subjects: 27
Study 34959879 — intervention group
Group type: COMPARATOR
Intervention: DASH
Number of subjects: 27
Study 36123366 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg every 2 weeks for 5 cycles (4 weeks/cycle) plus weekly nab-paclitaxel for 3 cycles, followed by atezolizumab 1200 mg every 3 weeks for 11 cycles after surgery.
Number of subjects: 0
Study 36123366 — intervention group
Group type: COMPARATOR
Intervention: Placebo with weekly nab-paclitaxel for 3 cycles, followed by standard of care.
Number of subjects: 0
Study 33620131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimlanod (BMS-986231)
Number of subjects: 45
Study 33620131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Number of subjects: 45
Study 33620131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 33620131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimlanod and NTG
Number of subjects: 45
Study 33104756 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI group (patients who met KDIGO criteria for AKI)
Number of subjects: 253
Study 33104756 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI group
Number of subjects: 253
Study 33104756 — intervention group
Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 253
Study 33104756 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of comorbid hypertension
Number of subjects: 253
Study 33104756 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of chronic kidney disease
Number of subjects: 253
Study 33104756 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 253
Study 36425922 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial SAP block with 30 ml 0.375% ropivacaine (group S)
Number of subjects: 40
Study 36425922 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep SAP block with 30 ml 0.375% ropivacaine (group D)
Number of subjects: 40
Study 36425922 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial SAP block (group S)
Number of subjects: 40
Study 36425922 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep SAP block (group D)
Number of subjects: 40
Study 33541759 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular group supervision
Number of subjects: 134
Study 33541759 — intervention group
Group type: COMPARATOR
Intervention: Individual telephone supervision based on only the behavioral component of a feedback protocol
Number of subjects: 134
Study 33541759 — intervention group
Group type: COMPARATOR
Intervention: Individual telephone supervision based on the full protocol
Number of subjects: 134
Study 33541759 — intervention group
Group type: COMPARATOR
Intervention: Objective feedback
Number of subjects: 134
Study 32865380 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg once daily
Number of subjects: 5522
Study 32865380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study 32996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral vitamin D gel
Number of subjects: 45
Study 32996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral vitamin D gel plus conventional treatment
Number of subjects: 45
Study 32996671 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 45
Study 32996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (vitamin D gel + conventional treatment)
Number of subjects: 45
Study 32996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D group
Number of subjects: 45
Study 33261257 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 55
Study 33261257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 55
Study 33261257 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of corticosteroids
Number of subjects: 55
Study 33261257 — intervention group
Group type: EXPERIMENTAL
Intervention: Injective therapy with local anaesthetics
Number of subjects: 55
Study 33261257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55
Study 33261257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 55
Study 34514743 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex visual scene search task ('Where's Waldo?')
Number of subjects: 20
Study 34514743 — intervention group
Group type: COMPARATOR
Intervention: Simple visual shapes presented at 0.5-, 2-, and 4-s intervals
Number of subjects: 20
Study 34514743 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement self-reported by participants (1 to 10 scale)
Number of subjects: 20
Study 34514743 — intervention group
Group type: EXPERIMENTAL
Intervention: All tasks (including both complex and simple)
Number of subjects: 20
Study 32134286 — intervention group
Group type: EXPERIMENTAL
Intervention: IMARA intervention
Number of subjects: 199
Study 32134286 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 199
Study 32431170 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health records (EHR)
Number of subjects: 30
Study 32431170 — intervention group
Group type: COMPARATOR
Intervention: Paper-based handwritten documentation (HWD)
Number of subjects: 30
Study 32431170 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR
Number of subjects: 30
Study 32431170 — intervention group
Group type: COMPARATOR
Intervention: HWD
Number of subjects: 30
Study 33121297 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol extra-virgin olive oil (EVOO)
Number of subjects: 40
Study 33121297 — intervention group
Group type: COMPARATOR
Intervention: Low polyphenol refined olive oil (ROO)
Number of subjects: 40
Study 32768713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 ppm Stannous fluoride (SnF2)
Number of subjects: 48
Study 32768713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm MFP + calcium silicate + sodium phosphate (CSSP)
Number of subjects: 48
Study 32768713 — intervention group
Group type: EXPERIMENTAL
Intervention: CSSP + dual-phase gel (CSSP + Serum)
Number of subjects: 48
Study 32768713 — intervention group
Group type: COMPARATOR
Intervention: non-fluoridated (NF)
Number of subjects: 48
Study 32768713 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2, CSSP, CSSP + Serum
Number of subjects: 48
Study 35693609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope (UTB) with virtual bronchoscopic navigation (VBN) and endobronchial ultrasound (EBUS)
Number of subjects: 578
Study 35693609 — intervention group
Group type: COMPARATOR
Intervention: Thin bronchoscope (TB) with VBN and EBUS using guide sheath (GS)
Number of subjects: 578
Study 35693609 — intervention group
Group type: COMPARATOR
Intervention: Thin bronchoscope (TB) with VBN and EBUS without guide sheath (non-GS)
Number of subjects: 578
Study 33050947 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir 1800 mg BD on Day 1 followed by 800 mg BD for the next 13 days
Number of subjects: 190
Study 33050947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 33050947 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 190
Study 35631072 — intervention group
Group type: EXPERIMENTAL
Intervention: ThymoQuinone Formula (TQF)
Number of subjects: 0
Study 35631072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33807284 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE) - ad libitum 8-h eating window
Number of subjects: 20
Study 33807284 — intervention group
Group type: COMPARATOR
Intervention: Non-Time-Restricted Eating (non-TRE)
Number of subjects: 20
Study 32463786 — intervention group
Group type: EXPERIMENTAL
Intervention: YMCA-DPP
Number of subjects: 158
Study 32463786 — intervention group
Group type: EXPERIMENTAL
Intervention: VLM-DPP
Number of subjects: 158
Study 32463786 — intervention group
Group type: COMPARATOR
Intervention: YMCA-DPP vs VLM-DPP
Number of subjects: 158
Study 35922776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactase (600 FCC units/mL), 5 drops mixed with breast milk or formula feed, four times a day for 4 weeks
Number of subjects: 162
Study 35922776 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 5 drops mixed with breast milk or formula feed, four times a day for 4 weeks
Number of subjects: 162
Study 35922776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactase (600 FCC units/mL)
Number of subjects: 162
Study 35922776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 34358734 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey Field Analyzer (HFA)
Number of subjects: 91
Study 34358734 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto Portable Perimeter (TPP)
Number of subjects: 91
Study 32475460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ME diet (3,111 kcal/kg ME)
Number of subjects: 50
Study 32475460 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ME diet (3,383 kcal/kg ME)
Number of subjects: 50
Study 32475460 — intervention group
Group type: COMPARATOR
Intervention: CST (Comparative Slaughter Technique)
Number of subjects: 50
Study 32475460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair-feeding with varying percentages (50%, 60%, 70%, 80%, 90%) of lead bird's intake
Number of subjects: 50
Study 32475460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ME diet and High-ME diet
Number of subjects: 50
Study 32475460 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional measurements (shank temperature, feeding station visits)
Number of subjects: 50
Study 34289778 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' perceived stress scores (PSS)
Number of subjects: 1797
Study 34289778 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological symptoms in children
Number of subjects: 1797
Study 34289778 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for higher caregivers’ PSS scores
Number of subjects: 1797
Study 32755100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E (400 IU/day of vitamin E and 1000 mg/day of vitamin C)
Number of subjects: 160
Study 32755100 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron tablets only)
Number of subjects: 160
Study 36004739 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 16
Study 36004739 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg) + Oxybutynin (5 mg)
Number of subjects: 16
Study 36004739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33502533 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 181
Study 33502533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 32739045 — intervention group
Group type: COMPARATOR
Intervention: Quick syringe changeover (QC)
Number of subjects: 286
Study 32739045 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pumping changeover (DPC)
Number of subjects: 286
Study 32739045 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated changeover (AC)
Number of subjects: 286
Study 35373238 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC oxygenation at 60L/min
Number of subjects: 190
Study 35373238 — intervention group
Group type: COMPARATOR
Intervention: Non-rebreather mask for preoxygenation and nasal prongs of at least 15L/min oxygen flow for apnoeic oxygenation
Number of subjects: 190
Study 35373238 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 190
Study 33533655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus definitive chemoradiotherapy
Number of subjects: 0
Study 33533655 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus definitive chemoradiotherapy
Number of subjects: 0
Study 34949631 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive SMS messaging intervention (Mobile WACh NEO)
Number of subjects: 5000
Study 34949631 — intervention group
Group type: COMPARATOR
Intervention: No SMS (control)
Number of subjects: 5000
Study 32362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-carpal ligament stretching
Number of subjects: 83
Study 32362377 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 83
Study 37337241 — intervention group
Group type: COMPARATOR
Intervention: Empirical therapy (Bismuth quadruple therapy as first-line, high-dose dual therapy as rescue)
Number of subjects: 500
Study 37337241 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-guided sequential strategy (clarithromycin triple therapy for clarithromycin-sensitive strains, high-dose dual therapy for clarithromycin-resistant strains, levofloxacin quadruple regimen for levofloxacin-sensitive strains, furazolidone quadruple regimen for others)
Number of subjects: 500
Study 32945620 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic play intervention (ITP)
Number of subjects: 20
Study 32945620 — intervention group
Group type: COMPARATOR
Intervention: Standard education (SE)
Number of subjects: 20
Study 32730913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Chamber Depth (ACD), Lens Vault (LV), Iris Curvature (IC) in model 1A
Number of subjects: 2225
Study 32730913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens Vault (LV) and Axial Length in model 1B
Number of subjects: 2225
Study 35313959 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSCs infusion (3 doses of 5×10^5 cells/kg with a dosing interval of 48 hours)
Number of subjects: 17
Study 35313959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 33687747 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly-guided therapy
Number of subjects: 628
Study 35500977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (PG, n = 29)
Number of subjects: 61
Study 35500977 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 32)
Number of subjects: 61
Study 36364884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive yoghurt containing curcumin and chlorogenic acid
Number of subjects: 0
Study 36364884 — intervention group
Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 0
Study 35397607 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-based box system intervention (CBBSI)
Number of subjects: 2224
Study 35397607 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 2224
Study 35397607 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about services during antenatal care visits
Number of subjects: 2224
Study 35397607 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of social support
Number of subjects: 2224
Study 33797489 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education program
Number of subjects: 0
Study 33797489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video education)
Number of subjects: 0
Study 33436465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) via mobile app guidance
Number of subjects: 370
Study 33436465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 370
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (T)
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (L)
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by Letrozole (TL)
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole followed by Tamoxifen (LT)
Number of subjects: 911
Study 33290610 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms (T, L, TL, LT)
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (age 65 or older)
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors larger than 2 cm
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 or more positive nodes
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone receptor (PR)–negative tumors
Number of subjects: 911
Study 33290610 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter disease-free survival (DFS)
Number of subjects: 911
Study 33564684 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 33564684 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 35794660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/amlodipine tablets (test and reference)
Number of subjects: 92
Study 34129252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day)
Number of subjects: 40
Study 34129252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32017643 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminders for second dose of influenza vaccine
Number of subjects: 256
Study 35470256 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation exercise group (SEG) - exercise protocol twice a week for 12 weeks
Number of subjects: 14
Study 35470256 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise group (REG) - usual exercise routine
Number of subjects: 14